Phase 2 N=28 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 5; 2; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=300 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Nicotine Dependence · Major Depressive Disorder
Primary: Bioverified Point-prevalence Abstinence at 27 Weeks — 6; 3; 13; 13 Participants
Phase 1 N=32 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects
Healthy
Primary: Measurement of the Safety Lab Parameter Activated Partial Thromboplastin Time (aPTT) — 1.000; 1.000; 1.000; 1.000 aPTT ratio
Phase 3 N=426 Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 60 — -0.70; -0.66 percentage of glycated hemoglin
Phase 2 N=26 A Pilot Study of KPL-914 in Recurrent Pericarditis
Recurrent Pericarditis
Primary: Parts 1, 2 and 4: Pretreatment C-Reactive Protein (CRP) Levels — 5.921; 0.645; 4.455; 5.156 mg/dL
N/A N=366 SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events. — 0; 0 Participants
Phase 2 N=24 Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
Epilepsy
Primary: Area Under the Concentration Time Curve (AUC) 0 to 4 Hours Post-dose — 739.33; 585 hr*ng/mL
N/A N=14 Chronic Kidney Disease Among Frail Elderly
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Phase 2 N=37 Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
Sarcoma
Primary: Maximum Tolerated Dose (MTD) of Doxorubicin Hydrochloride Plus Pembrolizumab According to the National Cancer Institute (NCI) Common Terminology for Adverse Events…
N/A N=60 Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI
Dyspnea
Primary: Number of Participants With Transient Dyspnea. — 23 Participants
Phase 2 N=51 A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
Idiopathic Pulmonary Fibrosis · Cough
Primary: Mixed Model of Repeated Measures (MMRM) Change From Baseline in Awake Objective Cough Frequency (Periods 1 & 2 Combined) — -9.1; -6.6; -6.6; -5.8 Coughs/hour — p=0.5096
Phase 2 N=183 Nigella Sativa in COVID-19
COVID-19 · SARS-CoV-2
Primary: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization — 54; 31 Participants — p=0.001
Phase 4 N=9 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
Actinic Keratosis
Primary: Percent Change From Baseline in Lesion Count at Week 18 — 95.5 percent change
Phase 3 N=14 Sancuso® for Gastroparesis: An Open Label Study.
Gastroparesis
Primary: GCSI-DD Total Composite Symptom Scores. — 1.89; 1.57; 1.34 score on a scale — p=<0.01
Phase 4 N=31 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants